Introduction
Human bocavirus (HBoV) is a newly recognised respiratory pathogen that mainly affects children aged <2 years. 1 It is a member of the Parvoviridae family, subfamily Parvovirinae, genus bocavirus. Since its first description in 2005 by Allander et al., it has been found worldwide in respiratory specimens from children with lower respiratory tract (LRT) infection with a prevalence varying from 1.5% to 19%. 2, 3 HBoV has also been isolated from faeces of children with gastroenteritis, with or without respiratory symptoms. 4 Recent studies have described two novel HBoV groups, named HBoV2 and HBoV3. 5 Publications addressing the epidemiology of nosocomial respiratory virus infection are scarce. A few authors have reported cases of nosocomial HBoV infection, mostly acquired in intensive care units. 6e8 As a potential new agent of nosocomial childhood infection, we screened for HBoV in young children with respiratory tract infection.
Methods
The data presented are part of a prospective study on the aetiology of childhood respiratory infections being carried out at Santa Casa de Misericórdia Hospital, São Paulo, Brazil. Santa Casa is a tertiary reference hospital located in the central region of São Paulo City.
From January 2008 to December 2008, nasopharyngeal aspirates (NPAs) were collected from children aged <2 years and screened for respiratory viruses including HBoV. Two groups of children were screened: (1) children on the paediatric ward or intensive care unit (ICU) with clinically suspected LRT infection (either community-or hospital-acquired), and (2) infants who had been in the neonatal ICU (NICU) since birth. On the NICU, NPAs were collected from those with suspected LRT infection, and once a week from asymptomatic infants who were receiving mechanical ventilation.
NPAs were stored in liquid nitrogen and sent weekly to the virology laboratory of the University of São Paulo for detection of respiratory virus by polymerase chain reaction (PCR). 9 All samples were tested for the following respiratory viruses: respiratory syncytial virus, human metapneumovirus, parainfluenza virus 1, 2 and 3, influenza virus A and B and adenovirus. PCR and reverse transcription (RT)ePCR assays were developed based on previous publications using GeneScan analysis with primers previously described. 10e12 PCR for HBoV was performed using primers previously described targeting the NS1 gene. 13 All HBoV-positive samples were amplified by a second PCR using primers based on a conserved region of the VP1/VP2 gene: HBoVP1 (5 0 4128 ACCACCAAGTACTTAGAACTGG 4149 3 0 ) and HBoVP2 (3 0 4785 AATAGTGCCTGGAGGATGATCC 4765 5 0 ). The expected product size was 657 bp. In most cases these products were sequenced for phylogenetic analysis. Sequences were edited with the sequence navigator program version 1.0 (Applied Biosystems, Inc., Foster City, CA, USA) and the phylogenetic tree was created by the clustal method using Megalign (Lacergene, DNA STAR, Inc., Madison, WI, USA).
The study was approved by the Research Ethics Committee of Santa Casa de Misericórdia Hospital and by the University of São Paulo. Written informed consent was obtained from the parent or guardian of each child enrolled in the study.
Results
A total of 511 NPA were collected from 406 children: 381 samples were collected from 359 children in the paediatric ward and ICU, while 130 were collected from 47 infants in the NICU. Fiftyfive samples (10.7%) were positive for HBoV, with a higher prevalence between May and August.
Ten of the HBoV infections were definitely or probably acquired in the hospital. Four infants had been in the NICU since birth (patients 1, 2, 3 and 10) while four infants admitted from the community had previously tested negative for HBoV (patients 4, 6, 7 and 9). One infant (patient 8) was in the paediatric ICU following liver transplantation and developed respiratory distress 28 days after admission. The final patient (patient 5) was in the paediatric ward being treated for visceral leishmaniasis and developed LRT infection 17 days after admission. The characteristics of the patients with hospital-acquired HBoV are described in Table I .
Among the 45 presumed community-acquired HBoV infections, 23 (51.1%) were coinfected with at least one other respiratory virus, particularly adenovirus and respiratory syncytial virus (RSV) (in nine cases each). Of the 10 hospital-acquired infections, only one was coinfected (adenovirus).
Phylogenetic analysis of eight of the 10 HBoV amplicons revealed three different strains of HBoV group 1 with 99.6e99.8% similarity (Figure 1 ). Two amplicons (representing patients 8 and 10) were not sequenced.
Discussion
Nosocomial HBoV infection has been recently described. Kesebir et al. reported three children who were infected in the hospital, all of whom had a history of premature birth and chronic lung disease. 6 Chow et al. reported three cases of nosocomial HBoV, two in the NICU. 8 Calvo et al. described two newborns with HBoV in the NICU, both premature and receiving mechanical ventilation. 7 In this paper we describe 10 further cases of nosocomial HBoV infection in children and infants. Sequence analysis of eight of the infecting viruses revealed three different strains of HBoV group 1, denominated A (six cases), B (one case) and C (one case).
Among these 10 children, only one was coinfected with another respiratory virus (adenovirus). Previous reports of HBoV infection suggest rates of coinfection with other respiratory viruses of up to 75%. 14 The low rate of coinfection in hospital-acquired compared with community-acquired HBoV may reflect the diminished circulation of respiratory virus in the hospital setting. We did not screen our samples for rhinovirus or coronavirus.
One child had undergone liver transplantation 27 days before HBoV was detected and was under intense immunosuppression. The role of HBoV infection in immunocompromised children is not well-defined. Recent studies report persistence of HBoV DNA in NPA of healthy individuals up to four months after infection. 15 In this case, since no previous sample was available, it is possible that the infection represented reactivation of previous community HBoV infection due to immunosuppression.
The finding of HBoV in four NICU infants hospitalised since birth raises the question of maternalefetal transmission. However, three of these children (patients 2, 3 and 10) had been in the NICU for more than two weeks when the virus was detected, and the fourth (patient 1) was seven months old, so it is more likely to have been acquired postnatally.
Hospital-acquired respiratory virus infection can increase morbidity and mortality in hospitalised children, mainly the younger ones and those with underlying conditions. We have demonstrated that HBoV can be detected from infants with clinical evidence of nosocomial respiratory infection as well as those with community-acquired infection.
